Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality
about
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular DiseaseRoles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic ApproachesPlasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study.Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short durationMyocardial Perfusion in Rheumatoid Arthritis Patients: Associations with Traditional Risk Factors and Novel Biomarkers.Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patientsCorrelates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney diseaseOsteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathwayNovel Aeruginosin-865 from Nostoc sp. as a potent anti-inflammatory agent.The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcificationRelationship between Biochemical Bone Markers and Bone Mineral Density in Patients with Phenylketonuria under Restricted Diet.Different health behaviours and clinical factors associated with bone mineral density and bone turnover in premenopausal women with and without type 1 diabetes.Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency.Blood-borne biomarkers of mortality risk: systematic review of cohort studies.Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes.Association of TRAIL and Its Receptors with Large-Artery Atherosclerotic Stroke.Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes.Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertensionOsteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patientsVariants on chromosome 6p22.3 associated with blood pressure in the HyperGEN study: follow-up of FBPP quantitative trait loci.Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.Osteoprotegerin as a marker of atherosclerosis in diabetic patients.Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin.NOTCH1 Mutations in Aortic Stenosis: Association with Osteoprotegerin/RANK/RANKL.Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease.The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review.Skeletal and extraskeletal actions of denosumab.The role of osteoprotegerin in cardiovascular disease.Smoking and inflammation: evidence for a synergistic role in chronic disease.Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study.Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease.Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants.Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes.A biomarker, osteoprotegerin, in patients undergoing hemodialysis.Serum osteoprotegerin and periodontal destruction in subjects with type 1 diabetes mellitus.Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls.Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
P2860
Q26747224-EECA021A-7245-4CE6-9177-60A69403343CQ26752576-B7DD1D81-EBE5-4DB5-A836-2FD7286CFA20Q30314414-2EA75531-CFF6-40F4-8D51-FE32F9331586Q33593925-74DC1CB7-E732-4191-BBC5-7F3FF607EB6CQ33695937-73A5387D-25C2-4BD7-BD89-D2DCF412DC74Q33882341-9FE0E1DF-A541-4400-AC5B-80C07CDDA5D6Q34028264-7D620D6A-DD24-42F1-8EF2-93848E5CD6CCQ34852319-FE27CE79-79E8-4CDD-A009-63B8A1DE6E98Q35016667-71E74FA4-AEFE-4A5A-A8E1-1F7BE9784CE9Q35083231-EE6F76C6-5240-4EB6-857C-1387DAD9EF1AQ35177301-383BBA49-2778-43EE-9744-62F7C8BCDC22Q35528586-DF3861B1-5DBA-4DBA-AEB4-FD75FBAF0906Q35643468-A50AD478-312A-47C9-8635-34D09210617AQ35651148-10A5E3D3-43D9-43A3-90BC-295278FF0D69Q35742069-8E7BD992-708A-477B-A39E-4702CC1F09E1Q35763132-82B6FBC6-9D79-434A-BA8D-617DCFC99D29Q35926521-09FFE8E9-B453-401E-88CB-B259F5116081Q35929743-A1820256-CD33-4E92-8972-8A1E0876543CQ35995048-A2B123F7-B18C-4547-8B13-392743F2A54CQ36121831-1DAD954D-5F0E-48B5-99C2-50C813BE17A9Q36388215-02EFF68D-8305-4D45-B025-BD397F4A7581Q36576768-B29FA2C3-C632-48BD-9297-289D5BC1A548Q36582644-C1E75F99-0798-47A5-9542-2902D516E7FBQ37408169-7B373FA8-B8B9-4856-A86F-2DC02E0C28EAQ37633121-C7E8B3F5-69AF-44D9-BCC3-1A8D6F43A452Q37664577-F2370AD8-F921-4CE4-A67D-43B3D93024EBQ37922640-3556ACE6-6591-43EA-89B9-11DA6FB39C6BQ38009712-ACC8F8F4-32CA-4FC7-A375-1219CB2A5E23Q38056541-4E6F49C6-CEDB-4FF1-B122-0FB1F0D39835Q38169801-C977C935-09A6-4F43-884B-239853128529Q39197051-131EE13D-6598-497A-86DC-3491B4E52775Q39787548-EC106925-268C-41E0-B127-F6BA134FC114Q40084826-AC59239B-B85A-461A-9206-D87E68621D3FQ41513500-5639BC0C-C461-42EE-B8D4-0F84775D0E4FQ41524527-1B4CEA20-2CFD-459F-94C7-842E7F7F5BBBQ42181735-C4494BED-38F7-4B6F-BFB9-ABEC9B0C76D7Q42854913-3DF8075C-D6B1-4781-9A49-4382CFB38E87Q43920016-660032B2-BB00-4874-BDDF-4C8290DF1803Q50135771-56CDC06A-38FD-43A8-9360-47220D9579E4Q51277910-604B7F82-61BA-4FB4-A6FE-75F4EDBA3EFD
P2860
Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Biomarkers of the osteoprotege ...... ascular disease, and mortality
@ast
Biomarkers of the osteoprotege ...... ascular disease, and mortality
@en
Biomarkers of the osteoprotege ...... ascular disease, and mortality
@nl
type
label
Biomarkers of the osteoprotege ...... ascular disease, and mortality
@ast
Biomarkers of the osteoprotege ...... ascular disease, and mortality
@en
Biomarkers of the osteoprotege ...... ascular disease, and mortality
@nl
prefLabel
Biomarkers of the osteoprotege ...... ascular disease, and mortality
@ast
Biomarkers of the osteoprotege ...... ascular disease, and mortality
@en
Biomarkers of the osteoprotege ...... ascular disease, and mortality
@nl
P2093
P2860
P50
P3181
P1476
Biomarkers of the osteoprotege ...... ascular disease, and mortality
@en
P2093
Caroline S Fox
Christopher J O'Donnell
Diane Corey
Izabella Lipinska
John F Keaney
Wolfgang Lieb
P2860
P304
P3181
P356
10.1161/ATVBAHA.109.199661
P407
P50
P577
2010-09-01T00:00:00Z